Vol. 2 No. 8 (2022)
Reimbursement Reviews

Cemiplimab (Libtayo)

Published August 31, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Cemiplimab (Libtayo), sterile solution for IV infusion, 50 mg/mL.
  • Indication: First-line treatment of adult patients with non–small cell lung cancer (NSCLC) expressing PD-L1 (TPS ≥ 50%), as determined by a validated test, with no EGFR, ALK, or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.